Moderna Merck mRNA Melanoma Vaccine Trial Success
Analysis based on 126 articles · First reported Aug 19, 2026 · Last updated Sep 08, 2026
The positive trial results triggered a surge in Moderna's stock (up over 100%) and a significant rise in Merck's shares, boosting the broader biotech sector, with the Sana Biotechnology hitting a record high. The breakthrough is expected to open a multi-billion-dollar market for personalized cancer vaccines, with analysts projecting billions in annual sales, and could help Moderna return to profitability while providing Merck a growth avenue as Pembrolizumab faces patent expiration.
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Pembrolizumab, met its primary and secondary endpoints in a Phase 3 trial involving 1,137 patients with high-risk melanoma that had been surgically removed. The combination significantly reduced the risk of cancer recurrence and metastasis compared to Pembrolizumab alone, marking the first positive late-stage trial for an mRNA cancer vaccine. The companies plan to present full data at an upcoming medical meeting and discuss regulatory filings. Moderna's stock more than doubled, adding nearly $40 billion to its market cap, while Merck shares rose about 11%. The success validates mRNA technology beyond infectious disease and could pave the way for personalized cancer vaccines across multiple tumor types. However, regulatory approval is pending, and U.S. Health Secretary Robert F. Kennedy Jr. has criticized mRNA vaccines and cut $500 million in related projects, potentially delaying approval. The trial results were hailed by oncologists as a 'landmark moment' and 'proof of principle' for personalized cancer vaccines.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard